2BBBullish & Bearish
Health Care

Bright Minds Biosciences Inc. (DRUG) Stock Score & Signals

Bright Minds Biosciences Inc. (DRUG) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 14 out of 100.

About Bright Minds Biosciences Inc.

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski.

2BB score and signals

Bright Minds Biosciences Inc.’s current 2BB score is 14 out of 100, built from the signal categories below.

SignalScoreReading
Activity9Very Low
Momentum58Stable
Financial strength0Very Weak
Quality60Strong
Risk45Moderate

Company facts

Founded2017
Employees26
52-week range$38.00 – $123.75

Recent earnings

Report dateEPS actualEPS estimateRevenue actualRevenue estimate
2027-02-10
2026-12-21
2026-08-12
2026-05-13